Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy
- PMID: 12720131
- DOI: 10.1053/sonc.2003.50068
Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy
Abstract
The natural history of asymptomatic IgM monoclonal gammopathies (MG) and variables predicting evolution to symptomatic lymphoproliferative disorders were investigated in 452 patients diagnosed from 1975 to 2001. Univariate and multivariate Cox models were used to identify possible predictors of disease progression. At a median follow-up of 49 months (range, 12 to 233), 41 cases (9.1%) evolved to symptomatic Waldenstrom's macroglobulinemia (n = 36), non-Hodgkin's lymphoma (n = 2), B-cell chronic lymphocytic leukemia (n = 1), IgM multiple myeloma (n = 1), and primary amyloidosis (n = 1); the median interval from diagnosis was 53 months (range, 12 to 154). The cumulative probabilities of transformation into a symptomatic lymphoproliferative disease at 5 and 10 years were 8% (95% confidence interval [CI], 6% to 12%) and 21% (95% CI, 16% to 29%), respectively. At univariate analysis, monoclonal component size and hemoglobin level as continuous parameters, lymphocytosis (>4 x 10(9)/L), bone marrow lymphoplasmacytoid infiltration (>10%), erythrocyte sedimentation rate (>40 mm/h), and detectable Bence Jones proteinuria were significantly related with evolution probability. At multivariate analysis, paraprotein level (P <.0001), hemoglobin level (P <.05), and lymphocytosis (P <.0001) independently predicted malignant evolution (P <.0001). In conclusion, patients with asymptomatic IgM-MG showing hematological features predictive of progression should be carefully monitored in view of an early treatment of the disease.
Copyright 2003 Elsevier Inc. All rights reserved.
Similar articles
-
Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.Leukemia. 2004 Sep;18(9):1512-7. doi: 10.1038/sj.leu.2403442. Leukemia. 2004. PMID: 15322559
-
Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.Semin Oncol. 2003 Apr;30(2):231-5. doi: 10.1053/sonc.2003.50056. Semin Oncol. 2003. PMID: 12720142
-
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.J Clin Oncol. 2002 Mar 15;20(6):1625-34. doi: 10.1200/JCO.2002.20.6.1625. J Clin Oncol. 2002. PMID: 11896113
-
[Malignant transformation of monoclonal gammopathy of undetermined significance].Presse Med. 2007 Dec;36(12 Pt 3):1985-96. doi: 10.1016/j.lpm.2007.01.040. Epub 2007 May 16. Presse Med. 2007. PMID: 17509811 Review. French.
-
Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition.Br J Haematol. 2007 Dec;139(5):663-71. doi: 10.1111/j.1365-2141.2007.06845.x. Br J Haematol. 2007. PMID: 18021080 Review.
Cited by
-
Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.Int J Hematol. 2012 Oct;96(4):501-5. doi: 10.1007/s12185-012-1158-y. Epub 2012 Aug 11. Int J Hematol. 2012. PMID: 22878940
-
Prevalence, clinical aspects, and natural history of IgM MGUS.Cytometry B Clin Cytom. 2010;78 Suppl 1(Suppl 1):S91-7. doi: 10.1002/cyto.b.20550. Cytometry B Clin Cytom. 2010. PMID: 20839342 Free PMC article. Review.
-
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.Cancers (Basel). 2021 Apr 23;13(9):2055. doi: 10.3390/cancers13092055. Cancers (Basel). 2021. PMID: 33922804 Free PMC article.
-
Waldenstrom macroglobulinemia.Cancer Lett. 2008 Oct 18;270(1):95-107. doi: 10.1016/j.canlet.2008.04.040. Epub 2008 Jun 13. Cancer Lett. 2008. PMID: 18555588 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous